OBJECTIVE: To evaluate the efficacy and safety of Runzao Zhiyang capsules combined with conventional therapy in the treatment of psoriasis. METHODS: Retrieved from PubMed

EMbase

CNKI and VIP etc.

randomized controlled trials about Runzao Zhiyang capsule in the treatment of psoriasis vulgaris were collected until Feb. 2022. Meta-analysis was performed by using RevMan 5.3 and Stata 15.0 software

and trial sequential analysis（TSA） was conducted for clinical response rate. RESULTS: A total of 16 studies were included

involving 1 275 patients. Meta-analysis results showed that Runzao Zhiyang capsules combined with conventional therapy could improve the clinical effective rate（RR=1.37

95%CI=1.28-1.47

P<0.000 01）

reduced PASI score（MD=-2.71

95%CI=-3.55--1.88

P<0.000 01） and the recurrence rate（RR=0.35

95%CI=0.22-0.55

P<0.000 01）

and there was statistical significance

compared with conventional therapy alone. There was no statistical significance in the incidence of adverse reactions between two groups（RR=0.46

95%CI=0.32-0.66

P<0.000 1）. The results of TSA further confirmed the evidence of clinical effective rate. CONCLUSIONS: Runzao Zhiyang capsules combined with conventional therapy is effective and safe in the treatment of psoriasis vulgaris

but the above results still need more large-scale and multi-center RCTs for further confirmation.